Previous 10 | Next 10 |
Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...
DNY59/E+ via Getty Images Kymera Therapeutics ([[KYMR]] -3.9%) has closed an upsized $257M offering of common shares with underwriters exercising in full their option to buy additional shares. A total of 6,181,500 shares at $47 per share were sold. Morgan Stanley, J.P. Morgan, Cowen, and Gugg...
WATERTOWN, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the closing of its upsized underwritten...
Shares of Kymera Therapeutics (KYMR) closed up 15.6% today after pricing an upsized equity offering of ~4.8M shares at $47 per share.The closing date is July 6.Kymera's most advanced program is KT-474 in phase 1 for IL-1R/TLR-driven conditions and diseases, such as atopic derma...
Shares of Kymera Therapeutics ([[KYMR]] +16.1%) For further details see: Kymera Therapeutics up 16% after pricing upsized equity offering
Kymera Therapeutics (KYMR) has priced its upsized public offering of ~4.8M common shares (from 4M) at $47.00/share, for expected gross proceeds of $223.5M.Underwriters' over-allotment is an additional 713,250 shares.Closing date is July 6. Morgan Stanley, J.P. Morgan, Cowen, and Guggenheim Se...
WATERTOWN, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the pricing of its upsized underwritten...
Shares of Kymera Therapeutics ([[KYMR]] +9.1%) are up in afternoon trading, a day after shares declined due to a Monday after-the-bell announcement of a 4M share stock offering.Shares fell sharply in Tuesday trading, closing ~7% lower.Kymera was buoyed on Monday by interim results from a Phas...
WATERTOWN, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that it has commenced an underwritten p...
Kymera Therapeutics (KYMR) announces positive interim results from the Single Ascending Dose ((SAD)) portion of the Phase 1 trial of KT-474, demonstrating the first degrader proof-of-mechanism in targeted protein degradation in a healthy volunteer study.Following a single 300 mg dose of KT-47...
News, Short Squeeze, Breakout and More Instantly...
Kymera Therapeutics Inc. Company Name:
KYMR Stock Symbol:
NASDAQ Market:
Kymera Therapeutics Inc. Website:
2024-07-12 19:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 13:30:00 ET Shares of Kymera Therapeutics (NASDAQ: KYMR) were soaring 18.4% higher as of 11:28 a.m. ET on Tuesday. The big jump came after the clinical-stage biopharmaceutical company announced on Monday that its partner, Sanofi , plans to expand the ongoing phase 2 s...
WATERTOWN, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside ...